Incretin hormones in the treatment of type 2 diabetes Part I: Influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism;Hormony inkretynowe w leczeniu cukrzycy typu 2 Czȩść I: Wpływ insulinotropowych hormonów jelitowych (inkretyn) na metabolizm glukozy

Endokrynologia Polska

Volumn 58, Issue 6, 2007, Pages 522-528

  Matuszek, Beata ^a   Lenart Lipiñska, Monika ^a   Nowakowski, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

GIP; GLP 1; Incretin effect; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN;

HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS;

EID: 43549112399     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Creutzfeldt W. Entero-insular axis and diabetes mellitus. Horm Metab Res 1992; 26 (supl.): 13-18. (Pubitemid 23017858)
2. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206. (Pubitemid 38943883)
3. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004; 47: 357-366. (Pubitemid 38491230)
4. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 123: 261-265.
5. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006; 6: 194-201.
6. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135-148. (Pubitemid 40380914)
7. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 2005; 10: 703-710. (Pubitemid 40724552)
8. Vilsboll T, Krarup T, Madsbad S i wsp. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119. (Pubitemid 34985287)
9. Mojsov S, Heinrich G, Wilson IB i wsp. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986; 261: 11880-11889. (Pubitemid 17206117)
10. Orskov C, Holst JJ, Knuhtsen S i wsp. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467-1475. (Pubitemid 17170509)
11. Cohen MA, Ellis SM, Le Roux CW i wsp. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696-4701. (Pubitemid 37357514)
12. Lugari R, Dell'Anna C, Ugolotti D i wsp. Effect of nutrient in-gestion on glucagon-like peptide1(7-36) amide secretion in human type 1 and type 2 diabetes. Horm Metab Res 2000; 32: 424-428.
13. Balks HJ, Holst JJ, von zur Muhlen A i wsp. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: choli-nergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 1997; 82: 786-790. (Pubitemid 27106588)
14. Kong MF, Chapman I, Goble E i wsp. Effects of oral fructose and glucose on plasma GLP-1 and appetite in normal subjects. Peptides 1999; 20: 545-551. (Pubitemid 29425883)
15. Elliott RM, Morgan LM, Tredger JA i wsp. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypep-tide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-166. (Pubitemid 23266831)
16. Mayo KE, Miller LJ, Bataille D i wsp. International Union of Pharmacology XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167-194. (Pubitemid 36268402)
17. Scrocchi LA, Brown TJ, MaClusky N i wsp. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2: 1254-1258. (Pubitemid 26375413)
18. Ding WG, Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 1997; 46: 615-621. (Pubitemid 27143377)
19. Holz GG. Epac: a new cAMP-binding protein in support of glu-cagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004; 53: 5-13. (Pubitemid 38044691)
20. Wheeler MB, Gelling RW, McIntosh CH i wsp. Functional expression of the rat pancreatic islet glucose-dependent insuli-notropic polypeptide receptor: ligand binding and intracellu-lar signaling properties. Endocrinology 1995; 136: 4629-4639.
21. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-166.
22. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913. (Pubitemid 30647076)
23. MacDonald PE, Salapatek AM, Wheeler MB. Glukacon-like pep-tide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002; 51: S443-S441.
24. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. AM J Physiol Endocri-nol Metab 2004; 286: E882-E890. (Pubitemid 38668808)
25. Gromada J, Dissing S, Bokvist K i wsp. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes 1995; 44: 767-774.
26. Gutniak MK, Juntti-Berggren L, Hellstrom PM i wsp. Gluca-gon-like peptide I enhances the insulinotropic effect of glibenc-lamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996; 19: 857-863. (Pubitemid 26286992)
27. Zander M, Madsbad S, Madsen JL i wsp. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830. (Pubitemid 34233752)
28. Nauck MA, Wollschlager D, Werner J i wsp. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553. (Pubitemid 26397366)
29. D'Alessio DA, Sandoval DA, and Seeley RJ. New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 2005; 115: 3406-3408. (Pubitemid 43121828)
30. Knauf C, Cani PD, Perrin C i wsp. Brain glucagons-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554-3563. (Pubitemid 43121843)
31. Egan JM, Bulotta A, Hui H i wsp. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003; 19: 115-123. (Pubitemid 36417195)
32. Stoffers DA, Kieffer TJ, Hussain MA i wsp. Insulinotropic glu-cagon-like peptide 1 agonists stimulate expression of home-odomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-748. (Pubitemid 30339989)
33. Zhou J, Wang X, Pineyro MA i wsp. Glucagon-like peptide 1 and exendin-4 convert pancrteatic AR42J cells into glucagon-and insulin-producing cells. Diabetes 1990; 48: 2358-2366.
34. Tourrel C, Bailbe D, Lacorne M i wsp. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with gluca-gon-like peptide-1or exendin-4. Diabetes 2002; 51: 1443-1452. (Pubitemid 34826610)
35. Li Y, Hansotia T, Yusta B i wsp. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478. (Pubitemid 36043598)
36. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab 2000; 11: 375-378.
37. Dupre J, Ross SA, Watson D i wsp. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocri-nol Metab 1973; 37: 826-828.
38. Mortensen K, Christensen LL, Holst JJ i wsp. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189-196. (Pubitemid 36773884)
39. Lippl F, Kircher F, Erdmann J i wsp. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regul Pept 2004; 119: 93-98. (Pubitemid 38482107)
40. Rudovich NN, Dick D, Moehlig M i wsp. Ghrelin is not suppressed in hyperglycemic clamps by gastric inhibitory poly-peptide and arginine. Regul Pept 2005; 127: 95-99. (Pubitemid 40185374)
41. Meier JJ, Nauck MA, Kranz D i wsp. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-662. (Pubitemid 38270634)
42. Meier JJ, Nauck MA. GIP as a potential therapeutic agent? Horm Metab Res 2004; 36: 859-866. (Pubitemid 40115911)
43. Hamet P, Larochelle P, Franks DJ i wsp. Cushing syndrome with with food-dependent periodic hormonogenesis. Clin Invest Med 1987; 10: 530-533. (Pubitemid 18062445)
44. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-2013.
45. Ding WG, Renstrom E, Rorsman P i wsp. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 1997; 46: 792-800. (Pubitemid 27188256)
46. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343. (Pubitemid 46871135)
47. Drucker DJ, Nauck MA. The incretin system: glucagon-like pep-tide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705. (Pubitemid 46048557)
48. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007; 6: 1344-1350. (Pubitemid 46871136)
49. Abbott CA, Baker E, Sutherland GR i wsp. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase-IV) gene. Immunogenetics 1994; 40: 331-338. (Pubitemid 24299322)
50. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care 2007; 30: 1335-1343.
51. Lunkas GR, Leiting B, Roy RS i wsp. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipetidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-2994. (Pubitemid 41401097)
52. Krarup T. Immunoreactive gastric inhibitory polypeptide. En-docr Rev 1988; 9: 122-134.
53. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetolo-gia 1997; 40: 984-986. (Pubitemid 27316583)
54. Meier JJ, Hucking K, Holst JJ i wsp. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-2504. (Pubitemid 33642767)
55. Vilsboll T, Agerso H, Krarup T et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220-224. (Pubitemid 36115169)
56. Theodorakis MJ, Carlson O, Muller DC i wsp. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004; 7: 1692-1698. (Pubitemid 38857446)
57. Weir GC, Bonner-Weir S. Five stage of evolving b-cell dysfunction during progression to diabetes. Diabetes 2004; 53 (supl. 3): S16-S21. (Pubitemid 39564517)
58. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003; 46 (supl. 1): M2-M8. (Pubitemid 36543097)
59. Del Prato S, Wishner WJ, Gromada J i wsp. b-cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 2004; 6: 319-331. (Pubitemid 39172853)
60. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823. (Pubitemid 38620857)
61. Prospective Diabetes Study UK (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837-853.
62. Fineman MS, Bicsak TA, Shen LZ i wsp. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing met-formin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377. (Pubitemid 36993328)